Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. More Details
Excellent balance sheet with weak fundamentals.
Share Price & News
How has Oncternal Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ONCT is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 38% a week.
Volatility Over Time: ONCT's weekly volatility has increased from 21% to 38% over the past year.
7 Day Return
1 Year Return
Return vs Industry: ONCT underperformed the US Biotechs industry which returned 21.2% over the past year.
Return vs Market: ONCT underperformed the US Market which returned 20.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Oncternal Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StOncternal Therapeutics, Inc. (NASDAQ:ONCT) Insiders Increased Their Holdings
3 months ago | Simply Wall StGeneral Counsel Hazel Aker Just Bought 451% More Shares In Oncternal Therapeutics, Inc. (NASDAQ:ONCT)
5 months ago | Simply Wall StWhat Kind Of Shareholder Appears On The Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) Shareholder Register?
Is Oncternal Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ONCT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ONCT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ONCT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ONCT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ONCT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ONCT is overvalued based on its PB Ratio (3.7x) compared to the US Biotechs industry average (3.5x).
How is Oncternal Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if ONCT's forecast earnings growth is above the savings rate (2.2%).
Earnings vs Market: Insufficient data to determine if ONCT's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ONCT's revenue (4.2% per year) is forecast to grow slower than the US market (10.2% per year).
High Growth Revenue: ONCT's revenue (4.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ONCT's Return on Equity is forecast to be high in 3 years time
How has Oncternal Therapeutics performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: ONCT is currently unprofitable.
Growing Profit Margin: ONCT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ONCT's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ONCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ONCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.8%).
Return on Equity
High ROE: ONCT has a negative Return on Equity (-119.9%), as it is currently unprofitable.
How is Oncternal Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ONCT's short term assets ($22.7M) exceed its short term liabilities ($7.6M).
Long Term Liabilities: ONCT's short term assets ($22.7M) exceed its long term liabilities ($301.0K).
Debt to Equity History and Analysis
Debt Level: ONCT's debt to equity ratio (1.6%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if ONCT's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ONCT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ONCT has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 29.6% each year.
What is Oncternal Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ONCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ONCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ONCT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ONCT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ONCT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jim Breitmeyer (66 yo)
Dr. James B. Breitmeyer, also known as Jim, M.D., Ph.D., serves as Director of Otonomy, Inc. since June 20, 2018. He serves as the Chief Executive Officer and President of Oncternal Therapeutics, Inc. Dr. ...
CEO Compensation Analysis
Compensation vs Market: Jim's total compensation ($USD1.12M) is above average for companies of similar size in the US market ($USD561.41K).
Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.
|President||no data||US$1.12m||1.25% |
|Chief Medical Officer||1.25yrs||US$1.33m||0% |
|CFO, Treasurer & Secretary||3.5yrs||no data||0.21% |
|Chief Scientific Officer||1.17yrs||no data||no data|
|Senior Vice President of Chemistry||1.25yrs||no data||no data|
|Chief Business Officer||1.17yrs||no data||no data|
Experienced Management: ONCT's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
|President||no data||US$1.12m||1.25% |
|Independent Director||1.83yrs||US$146.03k||0.32% |
|Independent Director||1.83yrs||US$148.58k||0.045% |
|Independent Director||1.83yrs||US$148.30k||0.073% |
|Independent Chairman||1.83yrs||US$272.80k||0% |
|Scientific Advisor||no data||no data||no data|
|Independent Director||2.5yrs||US$143.77k||0.066% |
|Independent Director||0.92yr||US$89.71k||0% |
|Non-Independent Director||1.42yrs||US$484.31k||0% |
|Scientific Advisor||no data||no data||no data|
|Independent Director||2.83yrs||US$141.50k||0% |
Experienced Board: ONCT's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ONCT insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 92.4%.
Oncternal Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Oncternal Therapeutics, Inc.
- Ticker: ONCT
- Exchange: NasdaqCM
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$76.084m
- Shares outstanding: 29.60m
- Website: https://www.oncternal.com
Number of Employees
- Oncternal Therapeutics, Inc.
- 12230 El Camino Real
- Suite 300
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ONCT||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Jun 2019|
|GTU2||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 2019|
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. The company’s product pipeline include c...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/25 00:13|
|End of Day Share Price||2020/11/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.